Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts. 

Eli Lilly

Wellington Management

Janus Henderson Investors

Logos Capital

Google Ventures

Biomatics Capital Partners

Casdin Capital

Novo Holdings

RA Capital Management

Redmile Group

Cormorant Asset Management

Verve Therapeutics

OutSystems is a low-code application development platform that enables organizations to build, deploy, and manage enterprise applications with speed.

OutSystems

Power Apps is a low-code platform that allows users to build custom apps for their business needs, integrating with Microsoft's suite of tools and services.

Power Apps by Microsoft

Salesforce Platform provides a low-code environment for building enterprise apps, enabling users to create and deploy custom applications on the Salesforce infrastructure.

Salesforce Platform

Quickbase is a low-code platform that empowers businesses to create custom applications to streamline processes and improve productivity.

Quickbase

Budibase is an open-source, low-code app builder that offers a platform for developing custom applications with ease.

Budibase

Huginn is a low-code platform known for process automation, providing tools for creating custom workflows and automating business processes.

Huginn

WordPress, known for its content management system, also offers low-code capabilities for building custom web applications and websites.

WordPress

Creatio is a low-code development platform that enables rapid development and innovation, offering tools for creating custom applications and automating business processes.

Creatio

Quixy is a cloud-based, no-code development platform designed for small to medium-sized businesses, allowing non-software developers to create custom applications.

Quixy

Vervet Logic, Inc. is the developer of VervetX, a platform designed to simplify the development and deployment of complex event-driven applications. The company focuses on providing a low-code/no-code environment that enables users to create, test, and run event-driven architectures with ease.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 8:32 AM	1d87bcf1
news daily refresh	general	Dec 4, 2024 2:16 PM	a0a5b43c
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	c9c6040a
crunchbase profile	general
li profile	general	May 14, 2024 8:32 AM	23b62e1f
translate crunchbase fundingrounds	general
peers	general
news basic	general	Dec 4, 2024 2:13 PM	250f7263
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VERVETX

Vervet Logic, Inc.

Last Close

7.71

14/02 21:00

Market Cap

507.99M

Beta: -

Volume Today

1.35M

Avg: -